Different effects of tibolone and continuous combined estrogen plus progestogen hormone therapy on sex hormone binding globulin and free testosterone levels - An association with mammographic density

Gynecological Endocrinology

Volumn 20, Issue 2, 2005, Pages 110-115

  Hofling, Marie ^a   Carlström, Kjell ^a   Svane, Gunilla ^a   Azavedo, Edward ^a   Kloosterboer, Helenius ^b   Von Schoultz, Bo ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Research and Development   (Netherlands)

Author keywords

Free testosterone; Hormone replacement therapy; Mammographic breast density; Sex hormone binding globulin; Tibolone

Indexed keywords

ESTRADIOL PLUS NORETHISTERONE ACETATE; ESTRONE SULFATE; PLACEBO; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE; TIBOLONE;

ADULT; AGE; AGED; ARTICLE; BODY MASS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MAMMOGRAPHY; PATIENT COMPLIANCE; POSTMENOPAUSE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

AGED; BREAST; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GONADAL STEROID HORMONES; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MAMMOGRAPHY; MENOPAUSE; MIDDLE AGED; NORETHINDRONE; NORPREGNENES; TESTOSTERONE;

EID: 18044391709     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590400021151     Document Type: Article

References (36)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-333.
2. Grimes DA, Lobo RA. Perspectives on the Women's Health Initiative trial of hormone replacement therapy. Obstet. Gynecol 2002;100:1344-1353.
3. Moore RA. Livial: a review of clinical studies. Br J Obstet Gynaecol 1999;106:1-21.
4. de Gooyer ME, Deckers GH, Schoonen WG, Verheul HA, Kloosterboer HJ. Receptor profiling and endocrine interactions of tibolone. Steroids 2003;68:21-30.
5. Lundström E, Christow A, Kersemaekers W, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 2002;186:717-722.
6. Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 1998;105:904-911.
7. Dören M, Rubig A, Coelingh Bennink HJ, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554-559.
8. von Schoultz B. Potency of different estrogen preparations. In: Studd JWW, Whitehead MI, editors. The menopause. Oxford: Blackwell Science; 1998. pp 130-137.
9. Tchernof A, Deprès J-P. Sex steroid hormones, sex hormone-binding globulin and the obesity in men and women. Horm Metab Res 2000;32:526-536.
10. Rosner W. Plasma steroid-binding proteins. Endocrinol Metab Clin North Am 1991;20:697-720.
11. Odlind V, Milsom I, Persson I, Victor A. Can changes in sex hormone binding globulin predict the risk of venous thromboembolism with combined oral contraceptive pills? Acta Obstet Gynecol Scand 2002;81:482-490.
12. Thomas HV, Reeves GK, Key TJ. Endogenous estrogen and postmenopausal breast cancer: a quantitative review. Cancer Causes Control 1997;8:922-928.
13. Pollak M. IGF-I physiology and breast cancer. Recent Results Cancer Res 1998;152:63-70.
14. Hankinson SE, Willett WC, Manson JE, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
15. Conner P, Christow AG, Skoog L, et al. Breast cell proliferation in postmenopausal women during HRT evaluated through fine needle aspiration cytology. Breast Cancer Res Treat 2003;78:159-165.
16. Zumoff B. Hormonal profiles in women with breast cancer. Obstet Gynecol Clin North Am 1994;21:751-772.
17. Labrie F, Luu-The V, Labrie C, et al. Endocrine and intracrine sources of androgens in women: Inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 2003;24:152-182.
18. Birrell SN, Bentel JM, Hickey TE, et al. Androgens induce divergent proliferative responses in human breast cancer cell lines. J Steroid Biochem Mol Biol 1995;52:459-467.
19. Jayo MJ, Register TC, Hughes CL, et al. Effects of an oral contraceptive combination with or without androgen on mammary tissues: a study in rats. J Soc Gynecol Invest 2000;7:257-265.
20. Boyd NF, Stone J, Martin LJ, et al. The association of breast mitogens with mammographic densities. Br J Cancer 2002; 87:876-882.
21. Carlström K, Sköldefors H. Determination of total estrone in peripheral serum from non-pregnant humans. J Steriod Biochem 1997;8:1127-1128.
22. Södergård R, Bäckström T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17 beta to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-810.
23. Stomati M, Hartmann B, Spinetti A, et al. Effects of hormonal replacement therapy on plasma sex hormone-binding globulin, androgen and insulin-like growth factor-1 levels in postmenopausal women. J Endocrinol Invest 1996; 19:535-541.
24. Bernardi F, Pieri M, Stomati M, et al. Effect of different hormonal replacement therapies on circulating allopregnanolone and dehydroepiandrosterone levels in postmenopausal women. Gynecol Endocrinol 2003;17:65-77.
25. Lobo RA. Estrogen and the risk of coaguloparhy. Am J Med 1992;92:283-285.
26. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997;78:315-326.
27. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996;24:1-19.
28. Carlström K, Karlsson R, von Schoultz B. Diurnal rhythm and effects of oral contraceptives on serum dehydroepiandrosterone sulfate (DHEAS) are related to alterations in serum albumin rather than changes in adrenocortical steroid secretion. Scand J Clin Lab Invest 2002;62:361-368.
29. Dimitrakakis C, Zhou J, Wang J, et al. A physiological role for testosterone in limiting estrogenic stimulation of the breast. Menopause 2002;10:292-298.
30. Gammon MD, Thompson WD. Polycystic ovaries and the risk of breast cancer. Am J Epidemiol 1991;134:818-824.
31. Lobaccaro JM, Lumbroso S, Belon C, et al. Male breast cancer and the androgen receptor gene. Nat Genet 1993;5: 109-110.
32. Haiman CA, Brown M, Hankinson SE, et al. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res 2002;62:1045-1049.
33. Isaksson E, von Schoultz E, Odlind V, et al. Effects of oral contraceptives on breast epithelial proliferation. Breast Cancer Res Treat 2001;65:163-169.
34. Rannevik G, Carlström K, Doeberl A, Laurell CB. Plasma protein changes induced by two orally administered androgen derivatives. Scand J Clin Lab Invest 1996;56: 161-166.
35. Chetrite GS, Kloosterboer HJ, Philippe JC, Pasqualini JR. Effects of Org OD14 (Livial) and its metabolites on 17 beta-hydroxysteroid dehydrogenase activity in hormone-dependent MCF-7 and T-47D breast cancer cells. Anticancer Res 1999;19:261-217.
36. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. J Am Med Assoc 2000;283: 485-491.